Trial · NCT03913702
Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement
NCT03913702, Phase 2, Terminated, The University of Texas Medical Branch, Galveston; results first posted 2025-01-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement. Trials, record NCT03913702. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03913702
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement
- NCT number
- NCT03913702
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Conditions
- Subacromial Impingement, Subacromial Impingement Syndrome
- Interventions
- Ketorolac Tromethamine, Methylprednisolone Acetate
- First posted
- 2019-04-12
- Last updated
- 2025-01-03
- Results first posted
- 2025-01-03
- Limitations and caveats
- The protocol was terminated early due inadequate patient enrollment.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | American Shoulder and Elbow Surgeon (ASES) | 12 weeks | The ASES is a self-assessment score, ranging between 0 and 100 (0 indicating the worst shoulder condition and 100 indicating the best shoulder condition), applicable for use in patients with shoulder pathology. A higher pain score indicates the subject is in more pain. A lower pain score indicates less pain. |
| Secondary | American Shoulder and Elbow Surgeon (ASES) | 2 weeks | The ASES is a self-assessment score, ranging between 0 and 100 (0 indicating the worst shoulder condition and 100 indicating the best shoulder condition), applicable for use in patients with shoulder pathology. A higher pain score indicates the subject is in more pain. A lower pain score indicates less pain. |
| Secondary | American Shoulder and Elbow Surgeon (ASES) | 4 weeks | The ASES is a self-assessment score, ranging between 0 and 100, (0 indicating the worst shoulder condition and 100 indicating the best shoulder condition), applicable for use in patients with shoulder pathology. A higher pain score indicates the subject is in more pain. A lower pain score indicates less pain. |
| Secondary | Range of Motion (ROM) | 12 weeks | The range of motion is a function-related measure, that reflects the extent of shoulder movement (measured in degrees, in forward flexion, and abduction with internal/external rotation of the shoulder) |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | American Shoulder and Elbow Surgeon (ASES) | 12 weeks | No data collected. | ||
| SECONDARY | American Shoulder and Elbow Surgeon (ASES) | 2 weeks | No data collected. | ||
| SECONDARY | American Shoulder and Elbow Surgeon (ASES) | 4 weeks | No data collected. | ||
| SECONDARY | Range of Motion (ROM) | 12 weeks | No data collected. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ketorolac | 1 | |
| Overall Study | STARTED | Methylprednisolone | 0 | |
| Overall Study | COMPLETED | Ketorolac | 0 | |
| Overall Study | COMPLETED | Methylprednisolone | 0 | |
| Overall Study | NOT COMPLETED | Ketorolac | 1 | |
| Overall Study | NOT COMPLETED | Methylprednisolone | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ketorolac | 0 | 1 |
| Total, all-cause mortality | Methylprednisolone | 0 | 0 |
| Total, other adverse events | Ketorolac | 0 | 1 |
| Total, other adverse events | Methylprednisolone | 0 | 0 |
| Total, serious adverse events | Ketorolac | 0 | 1 |
| Total, serious adverse events | Methylprednisolone | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03913702
GET https://conductscience.org/api/trials/v1/NCT03913702/registered